生物工程皮肤治糖尿病足溃疡
路透社纽约健康消息 许多糖尿病病人由于血循环不好，抗感染能力又差，容易出现足部溃疡而且很难愈合，有时甚至不得不截肢。最近美国南佛罗里达足踝病研究所的足病专家詹森·汉弗特医生在新奥尔良召开的全美足踝外科学会的年会上宣布，一种名为Dermagraft，来源于人体皮肤的生物工程皮肤，可以加速糖尿病足部溃疡的愈合。
通常医生对糖尿病足部溃疡所采用的治疗方法是用敷料包扎伤口使其保持湿润，而Dermagraft则可以帮助皮肤更快愈合，并且愈合面更大。Dermagraft是将婴儿的包皮细胞放在一个可吸收的网套上面培养出来的，这些来自一个包皮上的细胞可以长成相当于6个足球场面积的细胞组织。组织长成后就会先被冷冻起来，到需要用时再放入热水中解冻。将Dermagraft放在患者的溃疡面上，再包上不粘绷带和湿敷料，就可以诱导和增强机体自身的愈合能力，并为皮肤细胞的生长提供一个框架。
研究人员将28位患有糖尿病足部溃疡的病人随机分为两组，实验组病人在12个星期里接受8次Dermagraft的皮肤嫁接治疗，而对照组病人只接受绷带的治疗。两组病人都需要特殊的插入物来穿鞋，并每周随诊一次。12个星期后，接受Dermagraft治疗的病人中有71%的人溃疡愈合，而另一组愈合率仅14%；平均来说，用生物工程组织治疗的溃疡愈合面要大两倍。另外，用Dermagraft治疗的伤口愈合得明显比用绷带治疗的快，感染发生率也相对比较低。
, http://www.100md.com
该研究由Dermagraft的生产商，美国先进组织科学有限公司资助，目前Dermagraft还未获得美国食品和药品管理局的通过。
Bioengineered Skin Heals Diabetic Foot Ulcers
NEW YORK (Reuters Health) - An experimental, bioengineered tissue grown from human skin appears to speed healing of diabetic foot ulcers, according to results of a study.
Due to poor circulation and a reduced ability to fight infection, many people with diabetes develop foot ulcers that are difficult to heal. Sometimes the damage can be so severe that a foot has to be amputated.
, 百拇医药
Currently, treatment involves dressing a wound to keep it moist, but an experimental type of bioengineered skin tissue called Dermagraft appears to provide swifter and more extensive healing, according to Dr. Jason Hanft, a podiatrist at the Foot and Ankle Institute of South Florida in South Miami.
In an interview with Reuters Health, Hanft explained that skin cells from infant foreskins are grown on an absorbent mesh to form the tissue. The cells from one foreskin can eventually grow to form 250,000-square feet of skin cells, he said.
, http://www.100md.com
Once the tissue is formed, it is frozen until needed. After being placed in hot water to thaw, the tissue is applied to the ulcer and covered with a nonstick bandage and a moist dressing. Hanft noted that the tissue is not meant to replace skin. Instead, it induces and improves the body‘s natural healing abilities and provides a ``scaffold‘‘ for skin cells.
In the current study, 28 patients with diabetic foot ulcers were randomly assigned to have their wound treated with Dermagraft or with the gauze and bandages alone. Patients received as many as eight applications of the tissue during the 12-week study. Both groups of patients received special inserts to wear in their shoes and had follow-up visits once a week.
, 百拇医药
After 12 weeks, about 71% of chronic ulcers had healed in patients treated with the tissue compared with just 14% of those who only received gauze, according to Hanft. On average, the percentage of wound area that healed was twice as high in wounds treated with the bioengineered tissue, he noted.
In addition, the wounds treated with the tissue healed significantly faster than those covered with gauze, and infections occurred less frequently in patients treated with the tissue, the researchers report.
, 百拇医药
Hanft reported the findings this week in New Orleans, Louisiana, at the annual meeting of the American College of Foot and Ankle Surgeons His research is part of a nationwide trial of Dermagraft.
The maker of Dermagraft, Advanced Tissue Sciences Inc., provided funding for the research. The tissue has not been approved for use by the US Food and Drug Administration, http://www.100md.com
通常医生对糖尿病足部溃疡所采用的治疗方法是用敷料包扎伤口使其保持湿润，而Dermagraft则可以帮助皮肤更快愈合，并且愈合面更大。Dermagraft是将婴儿的包皮细胞放在一个可吸收的网套上面培养出来的，这些来自一个包皮上的细胞可以长成相当于6个足球场面积的细胞组织。组织长成后就会先被冷冻起来，到需要用时再放入热水中解冻。将Dermagraft放在患者的溃疡面上，再包上不粘绷带和湿敷料，就可以诱导和增强机体自身的愈合能力，并为皮肤细胞的生长提供一个框架。
研究人员将28位患有糖尿病足部溃疡的病人随机分为两组，实验组病人在12个星期里接受8次Dermagraft的皮肤嫁接治疗，而对照组病人只接受绷带的治疗。两组病人都需要特殊的插入物来穿鞋，并每周随诊一次。12个星期后，接受Dermagraft治疗的病人中有71%的人溃疡愈合，而另一组愈合率仅14%；平均来说，用生物工程组织治疗的溃疡愈合面要大两倍。另外，用Dermagraft治疗的伤口愈合得明显比用绷带治疗的快，感染发生率也相对比较低。
, http://www.100md.com
该研究由Dermagraft的生产商，美国先进组织科学有限公司资助，目前Dermagraft还未获得美国食品和药品管理局的通过。
Bioengineered Skin Heals Diabetic Foot Ulcers
NEW YORK (Reuters Health) - An experimental, bioengineered tissue grown from human skin appears to speed healing of diabetic foot ulcers, according to results of a study.
Due to poor circulation and a reduced ability to fight infection, many people with diabetes develop foot ulcers that are difficult to heal. Sometimes the damage can be so severe that a foot has to be amputated.
, 百拇医药
Currently, treatment involves dressing a wound to keep it moist, but an experimental type of bioengineered skin tissue called Dermagraft appears to provide swifter and more extensive healing, according to Dr. Jason Hanft, a podiatrist at the Foot and Ankle Institute of South Florida in South Miami.
In an interview with Reuters Health, Hanft explained that skin cells from infant foreskins are grown on an absorbent mesh to form the tissue. The cells from one foreskin can eventually grow to form 250,000-square feet of skin cells, he said.
, http://www.100md.com
Once the tissue is formed, it is frozen until needed. After being placed in hot water to thaw, the tissue is applied to the ulcer and covered with a nonstick bandage and a moist dressing. Hanft noted that the tissue is not meant to replace skin. Instead, it induces and improves the body‘s natural healing abilities and provides a ``scaffold‘‘ for skin cells.
In the current study, 28 patients with diabetic foot ulcers were randomly assigned to have their wound treated with Dermagraft or with the gauze and bandages alone. Patients received as many as eight applications of the tissue during the 12-week study. Both groups of patients received special inserts to wear in their shoes and had follow-up visits once a week.
, 百拇医药
After 12 weeks, about 71% of chronic ulcers had healed in patients treated with the tissue compared with just 14% of those who only received gauze, according to Hanft. On average, the percentage of wound area that healed was twice as high in wounds treated with the bioengineered tissue, he noted.
In addition, the wounds treated with the tissue healed significantly faster than those covered with gauze, and infections occurred less frequently in patients treated with the tissue, the researchers report.
, 百拇医药
Hanft reported the findings this week in New Orleans, Louisiana, at the annual meeting of the American College of Foot and Ankle Surgeons His research is part of a nationwide trial of Dermagraft.
The maker of Dermagraft, Advanced Tissue Sciences Inc., provided funding for the research. The tissue has not been approved for use by the US Food and Drug Administration, http://www.100md.com